

Stahl's Illustrated

Index

- acetylcholine: and arousal pathways, 97;
 and cholinergic side effects, 45, 46,
 47
- acetylcholine-linked antipsychotic agents,
 144
- adolescents: and antipsychotic-induced
 weight gain, 91; and monitoring of
 antipsychotic side effects, 94; and
 olanzapine, 116; and quetiapine, 118;
 and risperidone, 112
- affective symptoms, of schizophrenia: best
 treatment for, 151; and dopamine
 hypothesis, 5; and D2 antagonism in
 mesocortical pathway, 35, 40; and D2
 partial agonists, 68; and effects of
 5HT_{2A}/D2 antagonism on DA circuitry,
 59; and hypoactivity in glutamate
 projections, 11
- aggressive symptoms, of schizophrenia,
 146, 150
- agitation, 157, 158
- agonist, definition of, 61
- agonist spectrum, 61–5
- agranulocytosis, and clozapine, 110
- alpha 1 adrenergic receptors, 43, 44
- alpha 2 receptors, 26
- amenorrhea, as side effect, 39
- amisulpride: and agonist spectrum, 65, 66;
 and CYP450 enzymes, 105; receptor
 profile of, 134; side effects of, 91, 134,
 135
- amoxapine, 130
- AMPA-kines, 144
- amygdala (A), 2, 12, 22
- anhedonia, as side effect, 40, 73, 74
- antagonist: definition of, 61; and second
 messenger activation, 64; and signal
 transduction, 62
- antidepressants: and augmentation of
 atypical antipsychotics, 160; and
 cytochrome P450 enzymes, 107; and
 monoamine receptor hypothesis of
 depression, 24; and sulpiride, 136; and
 time course of treatment in depression, 25
- antipsychotic drugs: and agonist spectrum,
 65; and 5HT_{2C} properties, 85; future of,
 144; and importance of D3 receptors and
 tonic firing, 70–87; and integrated
 dopamine hypothesis of schizophrenia, 7;
 overview of, 32; summary of
 recommendations on, 163; and switching
 strategies, 145–61; and theory behind
 partial agonists, 61–9. *See also* atypical
 antipsychotics; conventional
 antipsychotics; dosing and dosages;
 recommendations; side effects; *specific
 drugs*
- anxiety, and cyamemazine, 132

- apathy, and D2 antagonists, 40
- aripiprazole: and agonist spectrum, 65, 66; and CYP450 system, 104, 105, 107, 108; and dosing, 123; mechanisms of action, 84, 122; and metabolic issues in schizophrenia, 152; side effects of, 91, 123, 153
- arousal pathways, and acetylcholine, histamine, and norepinephrine, 22, 97
- asenapine: and CYP450 enzymes, 105; and dosing, 140, 141; receptor profile of, 140; recommendations on, 141; and side effects, 91, 140, 141, 152, 153
- atypical antipsychotics: and agonist spectrum, 63, 65; combining with conventional antipsychotics, 161; and failure of monotherapy, 160; and insulin resistance, 93; mechanisms of action, 54–60; monitoring and management of side effects, 95; and NET properties, 86; and noncompliance, 99; overview of, 48, 53; pharmacological profile of, 52; and prolactin release, 58; and psychopharmacologists, 96; rapid dissociation theory of action, 49–51; and sedation, 97, 99
- autistic disorder, 112
- basal forebrain (BF): and dopamine pathways, 2; and norepinephrine pathways, 22; and sedation, 97; and serotonin projection, 12
- benzodiazepines, and sedation, 98, 102, 153, 157, 158, 159
- bifeprunox, 105, 143
- bipolar depression, 118, 142, 143
- bipolar disorder, 112, 116, 118
- bipolar mania, 140, 143
- blonanserin, 53
- blood pressure, and side effects, 43, 96
- blurred vision, and side effects, 43
- body mass index (BMI), 94, 95, 96
- brain regions: and neurobiology of mood disorders, 21–30; and neurobiology of schizophrenia, 2–20
- brainstem, and serotonin projections, 12. *See also* raphe nucleus
- brainstem neurotransmitter centers (NT), 2, 22
- carbamazepine, 108
- cardiometabolic risk, and side effects, 90–1, 94
- cardiovascular disease, 92
- cariprazine, 84, 143
- CATIE trial (Clinical Antipsychotic Trials of Intervention Effectiveness), 99
- cerebellum (C), 2, 12, 22
- children: and antipsychotic-induced weight gain, 91; and risperidone, 112. *See also* adolescents
- chlorpromazine, 31
- cholecystokinin, 144
- cholinergic side effects, 45–7
- chorea, 36
- cigarette smoking, 106, 144
- circadian rhythms, and 5HT7 receptors, 87
- clozapine: and CYP450 system, 104, 105, 106, 107, 108; and dosing, 111; and 5HT1A partial agonism, 84; and metabolic issues in schizophrenia, 152; receptor profile of, 110; side effects of, 91, 110, 111, 153
- cognition, regulation of by norepinephrine, 22. *See also* cognitive symptoms
- cognitive disorders, and effects of NET inhibition on norepinephrine and dopamine, 79, 82
- cognitive symptoms, of schizophrenia: best treatments for, 149; and dopamine hypothesis, 5; and D2 antagonism in mesocortical DA pathway, 35, 40; and D2 partial agonists, 68; and effects of 5HT2A/D2 antagonism on DA circuitry,

- 59; and hypoactivity in glutamate projections, 11. *See also* cognition
- constipation, and side effects, 43
- conventional antipsychotics: and agonist spectrum, 63; combining with atypical antipsychotics, 161; generic and trade names of, 33; mechanisms of action, 34–47; overview of, 32; and prolactin release, 58; side effects of, 33, 36, 38, 42, 43, 44, 45–7; tight and long-lasting binding of to D2 receptors, 42
- cortical brainstem glutamate projection, 8
- cortico-cortical glutamatergic pathways, 8, 19
- cortico-striatal glutamate pathways, 8
- cortico-thalamic glutamate pathways, 8
- cross-titration, and switching strategies, 155, 156
- cymemazine, 53, 105, 132–3
- d-cycloserine, 144
- cytochrome P450 system (CYP450), 103–108
- delusions, 4
- depression: brain circuits impaired in, 21; cariprazine and treatment-resistant, 143; monoamine hypothesis of, 23; monoamine receptor hypothesis of, 24; neurotransmitters and time course of treatment in, 25; norepinephrine and mediation of symptoms of, 22; and paliperidone, 114; and tonic firing, 72, 73. *See also* bipolar depression
- diabetes, 92. *See also* insulin resistance
- diabetic ketoacidosis (DKA), 93, 94
- divalproex, 118, 160
- dizziness, and side effects, 43
- dopamine (DA): and cholinergic side effects of antipsychotics, 45–7; and conventional antipsychotics, 33; and development of new antipsychotics, 32; effects of D2 antagonism on circuitry of, 40–41, 59–60; effects of D2 partial agonism on, 68–9; effects of 5HT2A antagonism on, 59–60; excessive phasic firing and excessive release of, 75; key pathways for, 3; and mesocortical pathway, 55; and monoamine hypothesis of depression, 23, 24; and monoamine interactions in mood disorders, 29; mood disorders and receptors for, 28; opposing actions of 5HT1A and 5HT2A receptors on release of, 13; and partial agonists, 64; and prolactin regulation, 57; rapid D2 dissociation and circuitry of, 50–1; regulation of release by 5HT in nigrostriatal pathway, 15–17; and role of glutamate in mesolimbic system, 10; schizophrenia and dysregulation of, 2–7; somatodendritic blockade of 5HT2A receptors and increased release of, 14
- dopamine hypothesis, of schizophrenia, 1, 4, 5, 7
- dopamine transporters (DAT): inhibitors of, 144; and norepinephrine transporters in prefrontal cortex, 78
- D1 agonists, 144
- D2 antagonism: effects of on dopamine circuitry, 40–41; in mesocortical DA pathway, 35; in mesolimbic DA pathway, 34; in nigrostriatal DA pathway, 36; in tuberoinfundibular DA pathway, 39
- D2 partial agonists (DPAs): benefits of, 67; effects of on dopamine circuitry, 68–9; overview of, 32, 66; and switching strategies, 159
- D2/D3 partial agonists, 74, 76
- D2 receptors: binding of conventional antipsychotics to, 42; and cholinergic side effects of antipsychotics, 46; and rapid dissociation theory of atypical antipsychotic action, 49; side effects due to chronic blockade of, 38, 100
- D3 antagonists, 144

- D3 partial agonists, 74
- D3 receptors, and tonic firing, 70–87
- dorsolateral prefrontal cortex (DLPFC), 3, 5, 35
- dosing and dosages: of amisulpride, 135; of aripiprazole, 123; of asenapine, 140, 141; of clozapine, 111; of cyamemazine, 133; and failure of monotherapy with atypical antipsychotics, 160; of iloperidone, 138, 139; of loxapine, 131; of lurasidone, 142; of olanzapine, 116, 117; of paliperidone, 115; of perospirone, 127; of quetiapine, 119; of risperidone, 113; of sertindole, 129; of sulpiride, 137; of ziprasidone, 120, 121; of zotepine, 125
- downregulation, and chronic receptor blockade, 37
- drowsiness, and side effects, 43
- dry mouth, and side effects, 43
- duloxetine, 107, 138
- dyskinesia, 6, 36. *See also* tardive dyskinesia
- dyslipidemia, 92
- endocrine regulation, and 5HT7 receptors, 87
- enzymes, and cytochrome P450 system, 103–108
- epilepsy, and 5HT7 receptors, 87
- erythromycin, 108
- extrapyramidal side effects (EPS): and conventional antipsychotics, 36, 38, 41, 42, 44, 46, 47; and D2 receptor blockade in nigrostriatal pathway, 67
- fasting glucose levels, 94, 95, 96
- fasting triglyceride levels (TGs), 94, 95, 96
- fluoxetine, 107, 108, 138
- flvoxamine, 106, 108
- full agonists, 61–4
- GABA (gamma-aminobutyric acid), 10, 13, 14, 17
- GABAergic interneurons, and norepinephrine and dopamine cortical neurons, 80, 81, 82
- galactorrhea, 39
- generic names, of conventional antipsychotics, 33
- genetic factors, and differential efficacy of antipsychotics, 96, 104
- glutamate: 5HT neuron and release of, 19; key pathways for, 8; and regulation of dopamine output, 7; role of in mesocortical system, 11; role of in mesolimbic system, 10
- glutamatergic system, and dopamine deficit, 5
- glycine agonists, 144
- g protein-linked signal transduction system, 62
- hallucinations, 4
- halperidol, 44
- hippocampus (H), 12, 22
- histamine (HA), and sedation, 97
 - H1 histamine receptors, 43, 90
- “hit and run” receptor binding property, of atypical antipsychotics, 49
- hyperglycemic hyperosmolar syndrome, 94
- hyperinsulinemia, 92
- hyperkinetic movement disorders, 36
- hyperprolactinemia, 39, 41
- hypothalamus (Hy): and dopamine pathways, 2; and norepinephrine pathways, 22; and sedation, 97; and serotonin projections, 12
- iloperidone: and CYP450 enzymes, 105; and dosing, 138, 139; receptor profile of, 138; recommendations on, 139; side effects of, 91, 138, 139, 152

Cambridge University Press

978-0-521-14905-1 - Stahl's Illustrated Antipsychotics: Treating Psychosis, Mania and Depression, Second Edition

Stephen M. Stahl and Laurence Mignon

Index

[More information](#)

- insomnia, and benzodiazepines, 158. *See also* sleep
- insulin resistance, and cardiometabolic risk of antipsychotic-induced weight gain, 91–3
- integrated dopamine hypothesis, of schizophrenia, 7
- intramuscular (IM) formulations, 112, 120
- inverse agonists, 61, 62, 144
- irreversible inhibitors, of enzymes, 103
- ketoconazole, 108
- lamotrigine, 160
- learning: and 5HT7 receptors, 87; and phasic firing in nucleus accumbens, 71
- lifestyle choices, and side effects, 96
- lithium, 118
- locus coeruleus, and monoamine interactions, 29
- loxapine, 53, 105, 130–1
- lurasidone, 87, 142
- management, of side effects, 95
- mania, 21, 143. *See also* bipolar mania
- memory, and 5HT7 receptors, 87
- mesocortical DA hypothesis, of negative, cognitive, and affective symptoms of schizophrenia, 5
- mesocortical DA pathway: description of, 3; D2 antagonism in, 35; effects of 5HT2A blockade in, 55
- mesocortical system, role of glutamate in, 11
- mesolimbic DA hyperactivity hypothesis, of positive symptoms of schizophrenia, 4, 9
- mesolimbic DA pathway: description of, 3; D2 antagonism in, 34; and dopamine hypothesis of schizophrenia, 4; excessive DA stimulation in, 67; indirect regulation of by 5HT2A blockade in cortex, 56
- mesolimbic system, role of glutamate in, 10
- metabolic highway, and side effects, 92, 94
- metabolic issues, in schizophrenia, 152
- mirtazapine, 140
- monitoring, of antipsychotic side effects, 94–5, 102
- monoamine(s), and neurotransmitter interactions in mood disorders, 29, 30
- monoamine hypothesis, of depression, 23
- monoamine receptor hypothesis, of depression, 24
- mood: and 5HT7 receptors, 87; regulation of by norepinephrine, 22
- mood disorders: and effects of NET inhibition on norepinephrine and dopamine, 79, 82; key brain regions and neurobiology of, 21–30
- mood stabilizers, 160. *See also* divalproex; lithium
- movement disorders, and side effects of conventional antipsychotics, 36
- multifunctional drugs, and 5HT1A agonism, 5HT2C antagonism, and norepinephrine reuptake inhibition, 83
- muscarinic cholinergic receptors, 44
— M1 receptor, 43
— M1 receptor antagonist, 47
— M3 receptors, 90, 93
- nefazodone, 108
- negative symptoms, of schizophrenia: best treatments for, 148; and dopamine hypothesis, 5; and D2 antagonism in mesocortical and mesolimbic pathways, 35, 40; and D2 partial agonists, 68; and effects of 5HT2A/D2 antagonism on DA circuitry, 59; and glutamatergic pathways in mesocortical system, 11; tonic and phasic firing, 73
- nemonapride, 53
- neurobiology: and key brain regions in mood disorders, 21–30; and key brain regions in schizophrenia, 2–20. *See also* neurotransmitters

- neurokinin antagonists, 144
- neuroleptosis, and side effects, 33
- neurotransmitters: and agonist spectrum, 61; and consequences of chronic receptor blockade, 37; interactions of in mood disorders, 29; mood disorders and absence or overabundance of in synaptic cleft, 30; partial agonists and second messenger activation, 64; and signal-to-noise ratio in schizophrenia, 20; and time course of treatment in depression, 25. *See also* dopamine; glutamate; norepinephrine; serotonin
- nigrostriatal dopamine pathway: and D2 antagonism, 36, 41; and D2 partial agonists, 69; D2 receptor blockade in, 38, 67; and regulation of dopamine release by 5HT neurons, 15–17; and key pathways in schizophrenia, 3, 6; and monoamine interactions, 29
- NMDA receptor hypofunction hypothesis, of schizophrenia, 9
- noncompliance, and side effects, 99
- norepinephrine: key pathways for, 22; and monoamine hypothesis of depression, 23, 24; and monoamine interactions in mood disorders, 29; role of receptors in mood disorders, 26; and sedation, 97; and serotonin interactions in schizophrenia, 77
- norepinephrine transporters (NET), 78–9, 86
- norfluoxetine, 108
- norquetiapine, 83, 118
- NRA0562, 53
- nucleus accumbens (NA): and dopamine pathways, 2; and norepinephrine pathways, 22; phasic firing in, 71; and serotonin projections, 12
- obesity, and cardiometabolic risk of antipsychotic-induced weight gain, 92, 94
- olanzapine: and CYP450 system, 104, 105, 106, 107; and dosing, 116, 117; and metabolic issues in schizophrenia, 152; receptor profile of, 116; side effects of, 91, 116, 117, 153
- pain, serotonin projections and regulation of, 12
- paliperidone: and CYP450 enzymes, 105; and dosing, 115; receptor profile of, 114; recommendations on, 115; side effects of, 91, 114, 115, 152, 153
- pancreatic beta cell failure, 92
- Parkinson's disease, 6, 36
- paroxetine, 107, 138
- partial agonists: and agonist spectrum, 63, 65; effects of on dopamine circuitry, 68–9; and 5HT1A partial agonism, 84; and second messenger activation, 64; and signal transduction, 62; theory behind, 61–9. *See also* D2 partial agonists; D2/D3 partial agonists; serotonin 1A partial agonists
- pearls. *See* recommendations
- peptide-linked agents, 144
- perospirone, 105, 126–7
- phasic firing, and D3 receptors, 71, 73, 75
- phencyclidine (PCP), 9
- pituitary gland, and prolactin secretion in tuberoinfundibular pathway, 57
- pituitary lactotroph cells, 57
- polypharmacy, and switching strategies, 156, 158, 161
- positive allosteric modulators (PAMs), 144
- positive symptoms, of schizophrenia: atypical antipsychotics and treatment of, 49; best treatments for, 147; and dopamine hypothesis of schizophrenia, 4; and D2 partial agonists, 68; and D2/D3 partial agonists, 76; and excessive phasic firing, 75; and 5HT2A blockade in cortex, 56; and 5HT2A/D2

- antagonists, 59; and mesocortical DA pathway, 35, 40; and mesolimbic DA pathway, 34, 40, 50; and side effects, 100
- prefrontal cortex (PFC): and dopamine pathways, 2; and D2 receptors, 35; GABAergic interneurons and enhanced release of norepinephrine and dopamine in, 80, 81; and norepinephrine pathways, 22; norepinephrine transporters and dopamine in, 78–9; and positive symptoms of schizophrenia, 56; and serotonin projection, 12; and signal-to-noise ratio in schizophrenia, 20
- presynaptic alpha 2 adrenergic receptors, 26
- presynaptic alpha 2 norepinephrine receptors, 26
- presynaptic dopamine D2 receptors, 28
- presynaptic 5HT1A somatodendritic autoreceptors, 27
- presynaptic 5HT1B/D receptors, 27
- prolactin: effects of conventional vs. atypical antipsychotics on release of, 58; and dopamine pathways, 6, 39, 57
- psychopharmacologists, and side effects, 96
- psychotomimetics, 65
- quetiapine: and CYP450 system, 105, 108; and dosing, 117; and 5HT1A partial agonism, 84; and metabolic issues in schizophrenia, 152; as multifunctional medication, 83; receptor profile of, 118; side effects of, 91, 119, 153
- raphe nucleus (brainstem), 12, 29
- rapid dissociation theory, of atypical antipsychotic action, 49–51
- rebound symptoms, and switching strategies, 154, 155
- receptor blockade, consequences of chronic, 37
- recommendations, for specific antipsychotics: on amisulpride, 135; on aripiprazole, 123; on asenapine, 141; on clozapine, 111; on cyamemazine, 133; on iloperidone, 139; on loxapine, 131; on olanzapine, 116; on paliperidone, 115; on perospirone, 127; on quetiapine, 119; on risperidone, 113; on sertinadole, 129; on sulpiride, 137; on ziprasidone, 121; on zotepine, 125
- reversible inhibitors, of enzymes, 103
- reward conditioning, and phasic firing in nucleus accumbens, 71
- risperidone: and CYP450 system, 104, 105, 107; and metabolic issues in schizophrenia, 152; receptor profile of, 112; side effects of, 91, 113, 153
- sarcosine, 144
- schizophrenia: as aggregation of different symptoms, 146; cigarette smoking as self-medication in, 106; dopamine hypothesis of, 1, 4, 5, 7; and dysregulation of dopamine, 2–7; key brain regions and neurobiology of, 2–20; and mesocortical DA pathway, 35; and mesolimbic DA pathway, 34, 50; metabolic issues in, 152; NMDA receptor hypofunction hypothesis of, 9; sedation and treatment of, 98; and side effects of antipsychotics, 100, 101, 102; signal-to-noise ratio in, 20; summary of points on use of antipsychotics for, 163; and switching strategies for antipsychotics, 145–61; tuberoinfundibular DA pathway in untreated, 39. *See also* affective symptoms; aggressive symptoms; cognitive symptoms; negative symptoms; positive symptoms
- second messenger activation, and partial agonists, 64

- sedation, and side effects, 97–8, 100, 101, 102, 153, 155, 158
- serotonin: axon terminal in striatum and release of dopamine, 18; key pathways for, 12–19; and monoamine hypothesis of depression, 23, 24; and monoamine interactions in mood disorders, 29; and norepinephrine interactions in schizophrenia, 77; and prolactin regulation, 57; and regulation of dopamine release in nigrostriatal pathway, 15–17; and role of receptors in mood disorders, 27
- serotonin 1A partial agonists (SPAs): and 5HT1A partial agonism, 84; overview of, 32; and switching strategies, 159
 - serotonin 2A dopamine 2 antagonists (SDAs): and combined 5HT2A/D2 receptor blockade, 54–5; drugs classified as, 53; effects of on dopamine circuitry, 59–60; future of, 53, 144; overview of, 32, 53; and prolactin release, 58; side effects of, 54
 - 5HT neuron: and dopamine release, 13, 15–17, 18; and glutamate release, 19
 - 5HT1A agonists/antagonists, 144
 - 5HT1A receptors: effects of stimulation of on norepinephrine and dopamine cortical neurons, 80; and dopamine release, 13, 19, 77
 - 5HT2A/D2 antagonists. *See* serotonin 2A dopamine 2 antagonists (SDAs)
 - 5HT2A receptors: and blockade in mesocortical DA pathway, 55; and dopamine release, 13, 14, 19; and regulation of mesolimbic DA pathway by blockade in cortex, 56
 - 5HT2C agonists/antagonists, 144
 - 5HT2C receptors: and cardiometabolic risk, 90; and norepinephrine and dopamine cortical neurons, 77, 81, 82, 85
 - 5HT6 antagonists, 144
 - 5HT7 antagonists, 144
 - 5HT7 receptor, 87
- sertindole, 105, 108, 128–9
- sertraline, 107
- side effects, of antipsychotics: and amisulpride, 91, 134, 135; and aripiprazole, 91, 123; and asenapine, 140, 141; and cardiometabolic risk, 90–1; and clozapine, 91, 110, 111; and conventional antipsychotics, 33, 36, 38, 42, 43, 44, 45–7; and cyamemazine, 133; and iloperidone, 139; and insulin resistance, 93; and loxapine, 130, 131; and lurasidone, 142; and metabolic highway, 92, 94; monitoring and management of, 94–5; and noncompliance, 99; and olanzapine, 91, 116, 117; and optimization of functional outcome, 100; and paliperidone, 114, 115; and pathway to efficacy, 101; and perospirone, 127; and psychopharmacologists, 96; and quetiapine, 91, 118, 119; and risperidone, 113; and sedation, 97–8, 100, 153, 155, 158; and sertindole, 128, 129; and strategies for best long-term outcome in schizophrenia, 102; and switching strategies, 154, 158; and ziprasidone, 91, 121; and zotepine, 124, 125. *See also* extrapyramidal side effects; sedation; tardive dyskinesia; weight gain
- sigma 1 agonists/antagonists, 144
- signal-to-noise ratio, in schizophrenia, 20
- signal transduction pathway, and agonist spectrum, 62
- sleep: and benzodiazepines, 158; and 5HT7 receptors, 87; and serotonin pathways, 12. *See also* somnolence

Cambridge University Press

978-0-521-14905-1 - Stahl's Illustrated Antipsychotics: Treating Psychosis, Mania and Depression, Second Edition

Stephen M. Stahl and Laurence Mignon

Index

[More information](#)

- somatodendritic receptors: and dopamine pathways, 28; and serotonin pathways, 14, 26, 27
- somnolence, and side effects of antipsychotics, 100, 101
- spinal cord (SC), 2, 12, 22
- stress, and 5HT7 receptors, 87
- striatum: and axon terminal, 18; and dopamine release, 15, 18; and monoamine interactions, 29; and norepinephrine pathways, 22; and serotonin projections, 12
- sublingual administration, 140
- substantia nigra, 15, 16, 29
- sulpiride: and agonist spectrum, 65, 66; and CYP450 enzymes, 105; and dosing, 137; side effects of, 136
- switching strategies, for use of antipsychotics for schizophrenia, 145–61
- symptom dimensions, of schizophrenia. *See* affective symptoms; aggressive symptoms; agitation; cognitive symptoms; delusions; hallucinations; negative symptoms; positive symptoms
- tardive dyskinesia, 38, 41, 42
- thalamo-cortical glutamate pathways, 8
- thalamus (T): and dopamine pathways, 2; and norepinephrine pathways, 22; and sedation, 97; and serotonin projection, 12
- thermoregulation, and 5HT7 receptors, 87
- time course, of treatment in depression, 25
- tonic firing, and dopamine D3 receptors, 70–87
- trade names, of conventional antipsychotics, 33
- tuberoinfundibular DA pathway: description of, 3; and D2 antagonism, 39, 41; and D2 partial agonists, 69; and prolactin secretion, 6, 39, 57
- upregulation, and chronic receptor blockade, 37, 38
- valproate, 112
- varenicline, 144
- ventromedial prefrontal cortex (VMPFC), 3, 5, 35
- weight gain: and blockade of 5HT2C and H1 receptors, 90; and cardiometabolic risk of antipsychotics, 91–2, 94; and monitoring of antipsychotic side effects, 95–6; and side effects of conventional antipsychotics, 43
- withdrawal, and switching strategies, 154
- Y931, 53
- ziprasidone: and CYP450 system, 105, 108; and dosing, 120, 121; and metabolic issues in schizophrenia, 152; pharmacology of, 83, 84, 120; side effects of, 91, 121, 153
- zotepine: and CYP450 enzymes, 105, 106, 108; and dosing, 125; receptor profile of, 124; recommendations on, 125; side effects of, 124, 125